Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022–2023 Influenza Season Among Adults ≥65 Years of Age
Compared to the SD egg-based vaccine, HD and adjuvanted vaccines conferred additional protection against influenza-related outcomes in the 2022-2023 season in adults ≥65 years. Our results provide real-world evidence of the comparative effectiveness of currently licensed vaccines.
Authors
- Bradley K. Ackerson (ORCID: https://orcid.org/0000-0002-0816-7345)
- Gina S. Lee (ORCID: https://orcid.org/0000-0002-7554-9116)
- Lina S. Sy (ORCID: https://orcid.org/0000-0003-2762-9266)
- Tianyu Sun (ORCID: https://orcid.org/0000-0002-3996-1381)
- Jennifer H Ku (ORCID: https://orcid.org/0000-0001-9469-5875)
- Lei Qian (ORCID: https://orcid.org/0000-0001-8001-3992)
- Evan J. Anderson (ORCID: https://orcid.org/0000-0002-1576-4420)
- Yi Luo (ORCID: https://orcid.org/0000-0001-8990-2470)
- Emily Rayens (ORCID: https://orcid.org/0000-0003-3369-3475)
- Hung Fu Tseng (ORCID: https://orcid.org/0000-0001-6184-6534)
- Julia E. Tubert (ORCID: https://orcid.org/0000-0003-0779-888X)
- Yoonyoung Park (ORCID: https://orcid.org/0000-0002-5990-1220)
- Punam P. Modha (ORCID: https://orcid.org/0009-0008-2274-1543)
Institutions
- Kaiser Permanente (US)
- Moderna Therapeutics (United States) (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2024-08-21
- DOI
- https://doi.org/10.1093/cid/ciae375
- Citations
- 7
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Moderna